Coronavirus and your health

Learn more about COVID-19 and diabetes.   |   Precautions for patients facing higher risks

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

Listen to Rodica Busui (Pop-Busui), MD, PhD, Neha J. Pagidipati, MD, MPH, and Jennifer B. Green, MD discuss ASCVD (atherosclerotic cardiovascular disease) progression in patients with type 2 diabetes,strategies to assess its risk, and the COORDINATE study.

Play the podcast in Apple Podcasts.

podcast player graphic

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

Rodica Busui (Pop-Busui), MD, PhD is the Larry D. Soderquist Professor of Diabetes, Vice Chair Clinical &
Health Outcomes Research Department of Internal Medicine, Director Clinical Research Caswell Diabetes Institute at the University of Michigan, and an international leader in the field of diabetes and diabetes complications. Her research interests involve chronic complications of diabetes, including
diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure, cardiovascular disease, as well as use of novel technologies for diabetes management.

Neha J. Pagidipati, MD, MPH is an Associate Professor of Medicine and cardiometabolic disease prevention specialist at the Duke Clinical Research Institute. She served as the Chief Research Fellow at the DCRI between 2016 and 2017 and has been involved with cardiometabolic disease prevention research since 2011. Currently, she directs the Duke Cardiometabolic Prevention Clinic, and her research focuses on cardiometabolic disease prevention, with particular emphasis on lifestyle modification, weight management, lipid disorders, and diabetes.

Jennifer B. Green, MD is a Professor of Medicine in the Division of Endocrinology at Duke University, a faculty member of the Duke Clinical Research Institute (DCRI) and was Chief of the Endocrinology section at the Durham VA Medical Center from 2003-2017. Dr. Green’s clinical practice and research have focused upon strategies to treat diabetes mellitus and reduce the risk of CV and other disease-related complications. She is presently the Duke University site PI, Publications Committee Co-Chair, and Executive Committee Member for GRADE, a federally-funded, long-term comparative effectiveness study of glucose-lowering medications for type 2 diabetes.